Vesicular glutamate transporters define two sets of glutamatergic afferents to the somatosensory thalamus and two thalamocortical projections in the mouse.
The ventral posterior nucleus of the thalamus (VP) receives two major sets of excitatory inputs, one from the ascending somatosensory pathways originating in the dorsal horn, dorsal column nuclei, and trigeminal nuclei, and the other originating from the cerebral cortex. Both systems use glutamate as neurotransmitter, as do the thalamocortical axons relaying somatosensory information from the VP to the primary somatosensory cortex (SI). The synapses formed by these projection systems differ anatomically, physiologically, and in their capacity for short-term synaptic plasticity. Glutamate uptake into synaptic vesicles and its release at central synapses depend on two isoforms of vesicular glutamate transporters, VGluT1 and VGluT2. Despite ample evidence of their complementary distribution, some instances exist of co-localization in the same brain areas or at the same synapses. In the thalamus, the two transcripts coexist in cells of the VP and other nuclei but not in the posterior or intralaminar nuclei. We show that the two isoforms are completely segregated at VP synapses, despite their widespread expression throughout the dorsal and ventral thalamus. We present immunocytochemical, ultrastructural, gene expression, and connectional evidence that VGluT1 in the VP is only found at corticothalamic synapses, whereas VGluT2 is only found at terminals made by axons originating in the spinal cord and brainstem. By contrast, the two VGluT isoforms are co-localized in thalamocortical axon terminals targeting layer IV, but not in those targeting layer I, suggesting the presence of two distinct projection systems related to the core/matrix pattern of organization of thalamocortical connectivity described in other mammals.
Graziano
Alessandro
A
Center for Neuroscience, University of California Davis, Davis, California 95616-8798, USA.
Liu
Xiao-Bo
XB
Murray
Karl D
KD
Jones
Edward G
EG
D000344:Afferent Pathways / Q000378:metabolism / Q000648:ultrastructure; D000818:Animals; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001931:Brain Mapping / Q000379:methods; D001933:Brain Stem / Q000378:metabolism / Q000648:ultrastructure; D004525:Efferent Pathways / Q000378:metabolism / Q000648:ultrastructure; D015870:Gene Expression / Q000502:physiology; D018698:Glutamic Acid / Q000378:metabolism*; D017403:In Situ Hybridization; D051379:Mice; D018613:Microscopy, Confocal; D016253:Microscopy, Immunoelectron; D017729:Presynaptic Terminals / Q000378:metabolism* / Q000648:ultrastructure; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D013003:Somatosensory Cortex / Q000378:metabolism / Q000648:ultrastructure; D013116:Spinal Cord / Q000378:metabolism / Q000648:ultrastructure; D009435:Synaptic Transmission / Q000502:physiology; D020651:Ventral Thalamic Nuclei / Q000378:metabolism* / Q000648:ultrastructure; D050598:Vesicular Glutamate Transport Protein 1 / Q000235:genetics / Q000378:metabolism*; D050599:Vesicular Glutamate Transport Protein 2 / Q000235:genetics / Q000378:metabolism*
D015415:Biomarkers; D012333:RNA, Messenger; C493477:Slc17a6 protein, mouse; C493465:Slc17a7 protein, mouse; D050598:Vesicular Glutamate Transport Protein 1; D050599:Vesicular Glutamate Transport Protein 2; D018698:Glutamic Acid